Terms ending in 2035
Every in-force patent on F. Hoffmann-La Roche AG's record whose computed term ends in 2035, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,004,817 | Diazacarbazole Derivatives as Tau-Pet-Ligands In force · High confidence | Hoffmann-La Roche Inc. | In force | High confidence | |
| US 10,005,770 | Process for the Preparation of N-[(3-Aminooxetan-3-YL)METHYL]-2-(1,1-Dioxo-3,5-Dihydro-1,4-Benzothiazepin-4-YL)-6-Methyl-QUINAZOLIN-4-Amine In force · High confidence | Hoffmann-La Roche Inc. | In force | High confidence | |
| US 10,684,291 | Biomarkers for Risk Assessment and Treatment Monitoring in Heart Failure Patients Guided by Natriuretic Peptides In force · High confidence | Roche Diagnostics Operations, Inc. | In force | High confidence | |
| US 12,117,454 | Biomarkers for Risk Assessment and Treatment Monitoring in Heart Failure Patients Guided by Natriuretic Peptides In force · Low confidence | Roche Diagnostics International AG | In force | Low confidence | |
| US 10,087,245 | Camelid Single-Domain Antibody Directed Against Phosphorylated Tau Proteins and Methods for Producing Conjugates Thereof F. Hoffmann-La Roche AG, Institut Pasteur, Commissariat a l'Energie Atomique et aux Energies Alternatives and Centre National de la Recherche Scientifique (CNRS) In force · High confidence | F. Hoffmann-La Roche AG, Institut Pasteur, Commissariat a l'Energie Atomique et aux Energies Alternatives and Centre National de la Recherche Scientifique (CNRS) | In force | High confidence | |
| US 10,538,582 | Camelid Single-Domain Antibody Directed Against Phosphorylated Tau Proteins and Methods for Producing Conjugates Thereof In force · High confidence | Centre National de la Recherche Scientifique (CNRS) | In force | High confidence | |
| US 9,458,153 | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection In force · High confidence | Hoffmann-La Roche Inc. | In force | High confidence | |
| US 11,124,563 | Camelid Single-Domain Antibody Directed Against Phosphorylated Tau Proteins and Methods for Producing Conjugates Thereof In force · Medium confidence | Centre National de la Recherche Scientifique (CNRS) | In force | Medium confidence | |
| US 9,957,266 | IMIDAZO[1,2-a]PYRIDIN-7-Amine In force · High confidence | Hoffmann-La Roche Inc. | In force | High confidence | |
| US 9,518,121 | ANTI-JAGGED1 Antibodies and Methods of Use In force · High confidence | F. Hoffmann-La Roche AG | In force | High confidence | |
| 52 more term ends in 2035 · Pro | |||||
10 of 62 patents shown. Soonest term end first, then patent number.
Pro members see all 62.
13 of these are in force and held by F. Hoffmann-La Roche AG.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.